Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities

被引:33
作者
Pugach, Pavel [1 ]
Ray, Neelanjana [2 ]
Klasse, Per Johan [1 ]
Ketas, Thomas J. [1 ]
Michael, Elizabeth [1 ]
Doms, Robert W. [2 ]
Lee, Benhur [3 ]
Moore, John P. [1 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY USA
[2] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA
关键词
CCR5; HIV inhibitors; antagonists; Escape mutants; IMMUNODEFICIENCY-VIRUS TYPE-1; SMALL-MOLECULE; CORECEPTOR; ANTIBODY; CD4; NEUTRALIZATION; SENSITIVITY; FUSION; GP120; MECHANISM;
D O I
10.1016/j.virol.2009.02.044
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
HIV-1 variants resistant to small molecule CCR5 inhibitors Such as vicriviroc (VVC) have modified Env complexes that can use both the inhibitor-bound and -free forms of the CCR5 co-receptor to enter target cells. However, entry via the inhibitor-CCR5 complex is inefficient in some, but not all, cell types, particularly cell lines engineered to express CCR5. We investigated the effect of increasing CCR5 expression, and hence the density of the inhibitor-CCR5 complex when a saturating inhibitor (VVC) concentration was present, by using 293-Affinofile cells, in which CCR5 expression is up-regulated by the transcriptional activator, ponasterone. When CCR5 expression was low, the resistant virus entered the target cells to a lesser extent when VVC was present than absent. However, at a higher CCR5 level, there was much less entry inhibition at a constant, saturating VVC concentration. We conclude that the relative decrease in entry of a VVC-resistant virus in some cell types results from its less efficient use of the VVC-CCR5 complex, and that increasing the CCR5 expression level can compensate for this inefficiency. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:296 / 302
页数:7
相关论文
共 37 条
  • [1] The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle
    Abrahamyan, LG
    Mkrtchyan, SR
    Binley, J
    Lu, M
    Melikyan, GB
    Cohen, FS
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (01) : 106 - 115
  • [2] ANASTASSOPOULOU CG, P NATL ACAD IN PRESS
  • [3] Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss
    Anastassopoulou, Cleo G.
    Marozsan, Andre J.
    Matet, Alexandre
    Snyder, Amy D.
    Arts, Eric J.
    Kuhmann, Shawn E.
    Moore, John P.
    [J]. PLOS PATHOGENS, 2007, 3 (06) : 720 - 732
  • [4] Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652
    Baba, Masanori
    Miyake, Hiroshi
    Wang, Xin
    Okamoto, Mika
    Takashima, Katsunori
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (02) : 707 - 715
  • [5] The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor
    Cormier, EG
    Dragic, T
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (17) : 8953 - 8957
  • [6] A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
    Dragic, T
    Trkola, A
    Thompson, DAD
    Cormier, EG
    Kajumo, FA
    Maxwell, E
    Lin, SW
    Ying, WW
    Smith, SO
    Sakmar, TP
    Moore, JP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) : 5639 - 5644
  • [7] The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility
    Gonzalez, E
    Kulkarni, H
    Bolivar, H
    Mangano, A
    Sanchez, R
    Catano, G
    Nibbs, RJ
    Freedman, BI
    Quinones, MP
    Bamshad, MJ
    Murthy, KK
    Rovin, BH
    Bradley, W
    Clark, RA
    Anderson, SA
    O'Connell, RJ
    Agan, BK
    Ahuja, SS
    Bologna, R
    Sen, L
    Dolan, MJ
    Ahuja, SK
    [J]. SCIENCE, 2005, 307 (5714) : 1434 - 1440
  • [8] Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel
    Hammer, Scott M.
    Saag, Michael S.
    Schechter, Mauro
    Montaner, Julio S. G.
    Schooley, Robert T.
    Jacobsen, Donna M.
    Thompson, Melanie A.
    Carpenter, Charles C. J.
    Fischl, Margaret A.
    Gazzard, Brian G.
    Gatell, Jose M.
    Hirsch, Martin S.
    Katzenstein, David A.
    Richman, Douglas D.
    Vella, Stefano
    Yeni, Patrick G.
    Volberding, Paul A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (07): : 827 - 843
  • [9] Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1
    Heredia, Alonso
    Latinovic, Olga
    Gallo, Robert C.
    Melikyan, Gregory
    Reitz, Marv
    Le, Nhut
    Redfield, Robert R.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (51) : 20476 - 20481
  • [10] Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4
    Huang, Chih-chin
    Lam, Son N.
    Acharya, Priyamvada
    Tang, Min
    Xiang, Shi-Hua
    Hussan, Syed Shahzad-ul
    Stanfield, Robyn L.
    Robinson, James
    Sodroski, Joseph
    Wilson, Ian A.
    Wyatt, Richard
    Bewley, Carole A.
    Kwong, Peter D.
    [J]. SCIENCE, 2007, 317 (5846) : 1930 - 1934